Invalidity dossier
US 5470483
Device and method for controlling the balance of fluids in an extracorporeal blood circuit
Current assignee: Gambro Industries SAS
Added 9/23/2026, 4:26:21 PM
Active provider: DeepSeek · deepseek-flash
Patent summary
Title, assignee, inventors, filing/issue dates, abstract, and a plain-language overview of the claims.
Patent Overview — US 5,470,483 A
Title: Device and method for controlling the balance of fluids in an extracorporeal blood circuit
Assignee: Hospal Industrie SAS (original assignee per the supplied record; a later Gambro Industries entry appears in the source but is not analyzed here).
Dates: Priority 1993-03-22; filed 1994-03-21; granted/published 1995-11-28. Status listed as expired (anticipated expiration 2014-03-21).
Inventors: Bernard Bene; Nicolas Goux.
Purpose: To control the balance of liquid withdrawn from and injected into blood during extracorporeal treatment (e.g., haemofiltration, haemodiafiltration), providing a device and method that is "reliable, inexpensive and simple to operate," usable during a treatment session or during maintenance operations.
Plain-language scope: The apparatus works with a blood-treatment device having a first line (blood from patient to treatment element, e.g., arterial line) and a second line (blood back to patient, e.g., venous line). It includes means for withdrawing liquid from the blood (extraction pump), means for injecting substitute liquid into at least one line (injection pump), and a bypass line directly connecting the first line to the second line. A sensor monitors pressure inside the recirculation circuit formed by the first line, treatment element, second line, and bypass line. Clamps isolate the patient and close the loop while pumps continue running. If extraction and injection rates are equal, pressure stays constant; if not, pressure drifts, allowing detection of imbalance and calibration of one pump against the other, with the ratio of set-point delivery rates stored and used to correct set points for real compensation.
Source: https://patents.google.com/patent/US5470483/en
What the excerpt does not establish: It does not provide the full claims, the complete description (text is marked as excerpted/omitted), the exact claim language defining infringement scope, the detailed description of the haemodiafiltration embodiment (FIG. 2), any prosecution history, or the legal effect of the listed assignments and status. No litigation, validity, ownership-transfer, or prior-art conclusions are drawn.
Generated 10/1/2026, 9:50:52 PM
Cases on file (0)
Specific litigation cases in our database that name US patent 5470483. The free-form analysis below may also discuss cases beyond this list.
No cases on file mention this patent. Upload a CSV or add a case manually in Admin → Manage litigation cases.
Litigation summary
Past and pending lawsuits — plaintiffs, defendants, jurisdictions, outcomes, and notable rulings.
Proceedings on file (0)
All PTAB activity →AIA trial proceedings (IPR / PGR / CBM) filed at the USPTO Patent Trial and Appeal Board against this patent. Sourced from the USPTO Open Data Portal and refreshed every six hours; each proceeding number deep-links to the PTAB E2E docket.
No PTAB proceedings on file. This patent has not been challenged via IPR, PGR, or CBM. The absence is itself a signal — well-asserted patents eventually attract IPRs. The LLM analysis below may surface filings the ODP feed hasn’t indexed yet.
PTAB challenges
AIA trial proceedings at the USPTO Patent Trial and Appeal Board — IPR, PGR, and CBM. Petitioners, judge panels, claim-level invalidation outcomes from Final Written Decisions, and Federal Circuit appeals. The single most important defensive datapoint after litigation history.
Assignment history
Inventors, original assignee, and the chain of ownership recorded with the USPTO — including the correspondent attorney who recorded each assignment, since shell-LLC chains often share one repeat-player attorney even when the entity names look unrelated. Surfaces NPE / patent-troll patterns: shell-entity transfers, known asserters in the chain, repeat correspondent fingerprints, pre-litigation assignments, and bankruptcy fire-sales.
Prior art
Earlier patents, publications, and products that may anticipate or render the claims unpatentable.
Obviousness
Combinations of prior art that suggest the claimed invention would have been obvious under 35 U.S.C. § 103.
Extensions
Patent term adjustments, term extensions, continuations, divisionals, family members, and expiration dates.
Derivative works
Defensive disclosure: derivative variations of each claim designed to render future incremental improvements obvious or non-novel.